Prevention of Gastrointestinal Bleeding in Patients Receiving Direct Oral Anticoagulants: A Narrative Review and Practical Framework for Prescribers
Clinics and Practice · 26.06.2026 · 16 (7) · 120
DOI: 10.3390/clinpract16070120 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinics and Practice, online erschienen am 26.06.2026. Verfasst von Nicoleta Dubei und 8 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Department, "Grigore T. Popa" University of Medicine and Pharmacy, 700503 Iași, Romania. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: As population aging increases the prevalence of atrial fibrillation (AF), the use of direct oral anticoagulants (DOACs) has expanded for thromboembolism prevention. Although DOACs offer advantages over vitamin K antagonists (VKAs), gastrointestinal bleeding (GIB) remains the most common extracranial adverse event. Current guidelines address global bleeding risk but provide limited guidance on site-specific gastrointestinal risk assessment and prevention. This narrative review aims to summarize current evidence on the mechanisms, etiologies, and risk factors for DOAC-associated gastrointestinal bleeding and to propose a pragmatic, risk-based framework to support clinicians in individualized bleeding prevention.
Methods
A narrative review of studies published between 2004 and 2025 was conducted, including randomized clinical trials, real-world evidence, meta-analyses, and major society guidelines. Evidence addressing DOAC safety profiles, gastrointestinal bleeding etiologies, patient-level risk factors, medication interactions, and preventive strategies was analyzed.
Results
Gastrointestinal bleeding in patients treated with DOAC is strongly influenced by underlying gastrointestinal pathology, comorbid conditions, and concomitant medications. Established risk factors include prior gastrointestinal hemorrhage, Helicobacter pylori infection, gastrointestinal malignancy, diverticulosis, and angiodysplasia, as well as the use of nonsteroidal anti-inflammatory drugs (NSAIDs), antiplatelet therapy, or selective serotonin reuptake inhibitors (SSRIs). DOACs differ in gastrointestinal safety: apixaban consistently demonstrates the most favorable profile, whereas rivaroxaban and high-dose dabigatran show higher GIB rates. Preventive strategies such as H. pylori testing and eradication, proton pump inhibitor use in high-risk individuals, avoidance of NSAIDs and unnecessary antiplatelet therapy, and individualized DOAC selection may help reduce bleeding risk.
Conclusions
Gastrointestinal bleeding risk in patients receiving DOAC therapy should be assessed using a site-specific and dynamic approach. A structured strategy integrating baseline risk evaluation, correction of modifiable factors, tailored anticoagulant selection, and risk-adapted follow-up may improve the safety of anticoagulation. The proposed framework may provide a pragmatic approach to individualized bleeding risk mitigation while preserving the benefits of DOAC therapy; however, prospective validation is required before its routine implementation can be recommended.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Internal Medicine Department, "Grigore T. Popa" University of Medicine and Pharmacy, 700503 Iași, Romania.
- Cardiology Department, Cardiovascular Diseases Institute "Prof. Dr. George I. M. Georgescu", Iași 700503, Romania.
ORCID-Profile: Nicoleta Dubei, Larisa Anghel, Laura-Cătălina Benchea, Bogdan-Sorin Tudurachi, Bianca-Ștefania Profire, Cristian Stătescu
Zitieren
APA
Dubei, N., Anghel, L., Benchea, L. C., Sascău, R. A., Prisacariu, C., Balasanian, M. O., Tudurachi, B. S., Profire, B. Ș., & Stătescu, C. (2026). Prevention of Gastrointestinal Bleeding in Patients Receiving Direct Oral Anticoagulants: A Narrative Review and Practical Framework for Prescribers. Clinics and Practice, 16(7), 120. https://doi.org/10.3390/clinpract16070120
Vancouver
Dubei N, Anghel L, Benchea LC, Sascău RA, Prisacariu C, Balasanian MO, et al. Prevention of Gastrointestinal Bleeding in Patients Receiving Direct Oral Anticoagulants: A Narrative Review and Practical Framework for Prescribers. Clinics and Practice. 2026;16(7):120. doi:10.3390/clinpract16070120
BibTeX
@article{Dubei2026,
author = {Dubei, Nicoleta and Anghel, Larisa and Benchea, Laura-Cătălina and Sascău, Radu Andy and Prisacariu, Cristina and Balasanian, Mircea Ovanez and Tudurachi, Bogdan-Sorin and Profire, Bianca-Ștefania and Stătescu, Cristian},
title = {Prevention of Gastrointestinal Bleeding in Patients Receiving Direct Oral Anticoagulants: A Narrative Review and Practical Framework for Prescribers},
journal = {Clinics and Practice},
year = {2026},
volume = {16},
number = {7},
pages = {120},
doi = {10.3390/clinpract16070120}
}
EUVIMED